| albumin-bound paclitaxel / Generic mfg. |
2016-002435-15: Pilot study to assess physical exercise intervention in neoadjuvant treatment with nab-paclitaxel in patients with triple negative breast cáncer Estudio piloto para evaluar la intervención, mediante ejercicio físico, en pacientes con cancer de mama triple negativas, durante el tratamiento neoadyuvante con nab-paclitaxel. |
|
|
| Ongoing | 4 | 20 | Europe | Powder for concentrate for solution for infusion, Abraxane | Fundación de Investigación HM Hospitales, Celgene | Supervised exercise regimen given during neoadjuvant chemotherapy for triple negative breast cancer patients. Ejercicio físico supervisado durante el tratamiento de quimioterapia neoadyuvante para pacientes con cáncer de mama triple negativo., Supervised exercise regimen given during neoadjuvant chemotherapy for triple negative breast cancer patients. Ejercicio físico supervisado durante el tratamiento de quimioterapia neoadyuvante para pacientes con cáncer de mama triple negativo., Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900021139: Doxorubicin Hydrochloride Liposome combined with Cyclophosphamide sequential albumin-bound paclitaxel for neoadjuvant therapy of breast cancer |
|
|
| Not yet recruiting | 4 | 60 | | Doxorubicin Hydrochloride Liposome+Cyclophosphamide+albumin-bound paclitaxel ;Doxorubicin Hydrochloride Liposome+Cyclophosphamide+albumin-bound paclitaxel | The First Affiliated Hospital of Xiamen University; The First Affiliated Hospital of Xiamen University, Self financing | breast cancer | | | | |
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs. |
|
|
| Not yet recruiting | 4 | 84 | Europe | Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine | Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH | Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800020429: A real world study for the effectivenss and safety of Nab-paclitaxel in patients with gastric cancer in Anhui Province. |
|
|
| Recruiting | 4 | 300 | | Nab-paclitaxel ± other treatments | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric cancer | | | | |
ChiCTR1900025940: Clinical effect of paclitaxel albumin in neoadjuvant chemotherapy for advanced ovarian cancer |
|
|
| Recruiting | 4 | 100 | | Albumin Paclitaxel combined with carboplatin ;Paclitaxel combined with Carboplatin | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Beijing Heathcock Clinical Oncology Research Foundation | Advanced ovarian cancer | | | | |
ChiCTR2000029714: Albumin-bound paclitaxel combined with loplatin versus docetaxel combined with loplatin in the perioperative treatment of advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 200 | | Albumin-bound paclitaxel, Loplatin and Tegafur ;Docetaxel, Loplatin and Tegafur | Xijing Hospital of Air Force Military Medical University; Xijing Hospital, Air Force Military Medical University, N/A | gastric cancer | | | | |
ChiCTR1900024720: Efficacy and safety of albumin-bound paclitaxel combined with cisplatin for neoadjuvant chemotherapy in squamous non-small cell lung cancer |
|
|
| Not yet recruiting | 4 | 40 | | albumin-bound paclitaxel combined with cisplatin | Beijing Cancer Hospital; Beijing Cancer Hospital, SHIYAO Group OUYI Pharmaceutical Co. Ltd. | Squamous non-small cell lung cancer | | | | |
ChiCTR2000034870: A prospective, randomized controlled study of mFOLFIRINOX versus gemcitabine combined with albumin paclitaxel in the treatment of patients with unresectable pancreatic cancer |
|
|
| Recruiting | 4 | 200 | | Oxaliplatin: 85 mg/m2, intravenous infusion, day 1; leucovorin: 400 mg/m2, intravenous infusion, day 1; irinotecan: 150 mg/m2 , Intravenous infusion, day 1; bolus injection of 5-FU: 2400 mg/m2, intravenous infusion, 46 hours; once every two weeks ;Albumin paclitaxel (nab-paclitaxel): 125mg/m2, intravenous infusion (30 minutes), on day 1, 8; gemcitabine (GEM): 1000 mg/m2, intravenous infusion, on day 1, 8; Once every three weeks | Wannan Medical College; Wannan Medical College, Self-financing | Pancreatic cancer | | | | |
ChiCTR1900023062: Efficacy And Safety of Weekly Nab-Paclitaxel Alone as First-line Chemotherapy for Elderly（≥70 years） Advanced Lung Squamous Carcinoma Patients. |
|
|
| Recruiting | 4 | 40 | | Nab-Paclitaxel ;Docetaxel or Gemcitabine | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Lung Squamous Carcinoma | | | | |
ChiCTR1900025762: Intraperitoneal and Intravenous nab-Paclitaxel Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: a Single Group, Single-Centre, Phase 2 Study |
|
|
| Not yet recruiting | 4 | 40 | | Intraperitoneal and intravenous nab-paclitaxel combine with S-1 | The Second Affiliated Hospital, Zhejiang University College of Medicine; The Second Affiliated Hospital, Zhejiang University College of Medicine, Self-finance | gastric | | | | |
ChiCTR2000028991: Efficacy and safety of nab-paclitaxel combined with apatinib in the second-line treatment of advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 60 | | Albumin-bound Paclitaxel+apatinib ;Paclitaxel+apatinib | The Affiliated Tumor Hospital of Xinjiang Medical University; The Affiliated Tumor Hospital of Xinjiang Medical University, The Affiliated Tumor Hospital of Xinjiang Medical University | Gastric Cancer | | | | |
NCT04766827: Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor |
|
|
| Recruiting | 4 | 116 | RoW | albumin-bound paclitaxel, Docetaxel | Tianjin Medical University Cancer Institute and Hospital | Squamous Cell Carcinoma of Head and Neck | 11/21 | 12/21 | | |
ChiCTR1900026165: Effect of albumin paclitaxel on efficacy, safety and immune function of elderly patients with advanced gastric cancer after first-line treatment failure |
|
|
| Recruiting | 4 | 60 | | Albumin - bound taxol single agent chemotherapy | Affiliated Hospital of Qinghai University; Affiliated Hospital of Qinghai University, self-raised | gastric cancer | | | | |
ChiCTR2000034444: To evaluate the efficacy and safety of albumin paclitaxel in first-line and maintenance therapy in patients with advanced lung squamous cell carcinoma |
|
|
| Not yet recruiting | 4 | 90 | | Albumin-bound paclitaxel maintenance therapy ;best supportive treatment | Yunnan Cancer Hospital; Yunnan Cancer Hospital, Shijiazhuang Pharmaceutical Group | non-small-cell lung cancer | | | | |
| Recruiting | 4 | 175 | Europe | PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy | IRCCS San Raffaele | Pancreatic Ductal Adenocarcinoma | 01/22 | 01/26 | | |
ChiCTR2000028900: A prospective, single-arm clinical study on the safety and efficacy of calirizumab combined with carboplatin and albumin paclitaxel in the neoadjuvant therapy of potentially resectable stage II-IIIA esophageal squamous cell carcinoma |
|
|
| Recruiting | 4 | 20 | | the neoadjuvant therapy of calirizumab combined with carboplatin and albumin paclitaxel | The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, Hengrui pharmaceutical limited liability company | esophageal squamous cell carcinoma | | | | |
ChiCTR2100044076: Safety and efficacy of liposomal doxorubicin combined with nab-paclitaxel in the treatment of locally advanced or recurrent/metastatic adenoid cystic carcinoma of head and neck: a prospective, multicenter phase II trial |
|
|
| Recruiting | 4 | 30 | | liposomal doxorubicin plus nab-paclitaxel | Chinese PLA General Hospital; Chinese PLA General Hospital, CSPC Ouyi pharmacetical company | adenoid cystic carcinoma of head and neck | | | | |
ChiCTR2000035359: An exploratory study on the safety and efficacy of Paclitaxel for injee in (Albumin Bound) combined with Nedaplatin arterial perfusion in the treatment of stage IIIb non-small cell lung cancer |
|
|
| Recruiting | 4 | 30 | | Albumin paclitaxel 200mg/m2 + nedaplatin 70mg/m2, bronchial artery perfusion, d1, q3w | People's Hospital of Jianyang; People's Hospital of Jianyang, Self-designed subject of Jianyang People's Hospital | Stage IIIb non-small cell lung cancer | | | | |
ChiCTR2100052395: Efficacy and safety of SHR-1210, Apatinib and nab-paclitaxel in the second-line treatment of recurrent / metastatic cervical cancer: a single arm, exploratory study |
|
|
| Recruiting | 4 | 31 | | SHR-1210 combined with Apatinib and Paclitaxel(albumin bound) | Wuhan union hospital, Huazhong University of science and technology; Level of the institution：, Jiangsu Hengrui Pharmaceutical Co., Ltd | cervical cancer | | | | |
ChiCTR2000030618: A prospective, single-arm, multicentre clinical study of first-line treatment of her2-positive recurrent/metastatic breast cancer with pyrotinib maleate tablet and trastuzumab plus albumin-bound paclitaxel |
|
|
| Recruiting | 4 | 115 | | Pyrroitinib maleate tablets combined with trastuzumab and albumin-bound paclitaxel | Jiangsu Provincial People's Hospital; Cuhk hospital affiliated to southeast university, Self-financing | Breast cancer | | | | |
ChiCTR2000041081: The clinical study of exploring Sintilimab combined with nab-paclitaxel and carboplatin for neoadjuvant treatment of resectable esophageal cancer |
|
|
| Recruiting | 4 | 27 | | Sintilimab + chemotherapy | The First Affiliated Hospital of Medical College of Zhejiang University; The First Affiliated Hospital of Medical College of Zhejiang University, Company funding | esophageal cancer | | | | |
ChiCTR2200056592: A prospective, open, multi-center clinical study of pyrotinib combined with trastuzumab and nab-paclitaxel in neoadjuvant treatment for stage II-III HER2-positive breast cancer patients |
|
|
| Recruiting | 4 | 46 | | Neoadjuvant treatment with pyrrotinib maleate combined with trastuzumab and albumin paclitaxel | Tumour Hospital of Mudanjiang City; Tumour Hospital of Mudanjiang City, horizontal project | HER2-positive breast cancer | | | | |
PIONEER, NCT05029453: Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy |
|
|
| Not yet recruiting | 4 | 60 | RoW | Apatinib | Wuhan Union Hospital, China, Jiangsu HengRui Medicine Co., Ltd. | Gastric Cancer, Randomized Controlled Study | 12/22 | 03/23 | | |
ChiCTR2100044536: Clinical study of albumin paclitaxel combined with cisplatin preoperative chemoradiotherapy for local late esophageal cancer |
|
|
| Not yet recruiting | 4 | 26 | | Albumin-bound paclitaxel combined with cisplatin | The Ninth Hospital of the Joint Logistic Support Force of the People's Liberation Army; The Ninth Hospital of the Joint Logistic Support Force of the People's Liberation Army, The Ninth Hospital of the Joint Logistic Support Force of the People's Liberation Army | esophagus cancer | | | | |
ChiCTR2100051293: Intervention study on preoperative application of PD-1 monoclonal antibody combined with gemcitabine and paclitaxel (albumin binding type) in the treatment of borderline resectable and locally advanced pancreatic cancer |
|
|
| Recruiting | 4 | 30 | China | gemcitabine + Albumin paclitaxel + Toripalimab monoclonal antibody | West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Latitudinal project | pancreatic cancer | | | | |
ChiCTR2100041608: A Single-arm, single-center, open-label clinical study of albumin-bound paclitaxel combined with carrelizumab and apatinib in the treatment of advanced biliary tract cancer |
|
|
| Recruiting | 4 | 36 | | albumin-bound paclitaxel combined with carrelizumab and apatinib | The First Affiliated Hospital Zhejiang University; The First Affiliated Hospital Zhejiang University, self-financing | biliary tract cancer | | | | |
ChiCTR1900021857: A clinical trial for nab-paclitaxel and carboplatin compared with sb-paclitaxel and carboplatin in advanced squamous cell lung cancer |
|
|
| Not yet recruiting | 4 | 200 | | nab-paclitaxel: 100mg/m2 iv d1, 8, 15 Carboplatin AUC=5-6 iv d1, (man AUC=5; female AUC=6) q3w 4cycles ;sb-Paclitaxel: 175mg/m2 iv d1, q3w 4cycles; Carboplatin AUC=5-6 iv d1, (man AUC=5; female AUC=6) q3w 4cycles | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, self-raise | squamous cell lung cancer | | | | |
ChiCTR2100041869: Safety and efficacy of nab-paclitaxel combined with cisplatin and 5-FU versus paclitaxel plus cisplatin and 5-FU for induction chemotherapy in locally advanced head and neck squamous cell carcinoma: a multicenter, open, randomized controlled clinical trial |
|
|
| Recruiting | 4 | 170 | | Paclitaxel (albumin-bound) + cisplatin + 5-FU ;paclitaxel+cisplatin+5-FU | Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital, CSPC Ouyi pharmacetical company | Head and neck squamous cancer | | | | |
ChiCTR2100046202: Efficacy and safety of Sintilimab and oxaliplatin in combination with capecitabine or in combination with paclitaxel/albumin paclitaxel in first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 100 | | Immunotherapy combined with chemotherapy | Nanping First Hospital Affiliated to Fujian Medical University; Nanping First Hospital Affiliated to Fujian Medical University, Cinda Biopharmaceutical (Suzhou) Co., Ltd | gastric and gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2100053712: Clinical study of the efficacy and safety of donafenib plus S-1 in first-line treatment of metastatic pancreatic cancer that failed NG(nab-Paclitaxel plus Gemcitabine) regimen |
|
|
| Recruiting | 4 | 10 | | Donafenib, Teggio | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, self-funded | pancreatic cancer | | | | |
ChiCTR2000034360: Study of single-agent nab-paclitaxel for the treatment of metastatic pancreatic cancer |
|
|
| Recruiting | 4 | 39 | | nab-paclitaxe 200mg/d, d1, 8; until disease progression, death or unacceptable toxicity | Beijing Cancer Hospital; Beijing Cancer Hospital, SHIYAO Group OUYI Pharmaceutical Co. Ltd. | Metastatic pancreatic cancer | | | | |
ENCO, ChiCTR2000034944: Efficacy and Safety of Nab-Paclitaxel /Carboplatin for First-Line Chemotherapy of Advanced Ovarian Cancer |
|
|
| Not yet recruiting | 4 | 164 | | Nab-Paclitaxel plus Carboplatin ;Paclitaxel plus Carboplatin | the First Hospital of Jilin University; The First Hospital of Jilin University, CSCO Foundation | Ovarian Cancer | | | | |
ChiCTR2300078985: Relationship between dynamic changes in body composition and pharmacokinetics and toxicity and side effects of nab-paclitaxel in northern China |
|
|
| Completed | 4 | 50 | | None; None | Ordos Central Hospital; Ordos Central Hospital, Discipline construction funds for medical institutions directly under Ordos City | Malignant tumor | | | | |
ChiCTR2000032702: Efficacy and safety of Paclitaxel (Albumin-bound) combined with Oxaliplatin and S-1 in preoperative adjuvant treatment of gastric cancer |
|
|
| Recruiting | 4 | 70 | | Paclitaxel(Albumin-bound) | Gansu Provincial Hospital; Gansu Provincial Hospital, Self-raising | Gastric cancer | | | | |
ChiCTR2300070894: (Withdrawn by researcher) Prospective study of camrelizumab in combination with chemotherapy for the neoadjuvant treatment of resectable/potentially resectable locally advanced esophageal squamous cell carcinoma |
|
|
| Completed | 4 | 60 | | Patients were treated with 2 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1 every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1 every 3 weeks), and carboplatin (area under the curve of 5 mg/mL/min on day 1 every 3 weeks). ;Patients were treated with 4 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1 every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1 every 3 weeks), and carboplatin (area under the curve of 5 mg/mL/min on day 1 every 3 weeks). | People’s Hospital of Yangzhong; People’s Hospital of Yangzhong, NA | Esophageal squamous cell carcinoma | | | | |
ChiCTR2000040330: A multicenter, prospective, randomized controlled trial of camrelizumab (SHR-1210) combined with chemotherapy versus chemotherapy alone for neoadjuvant treatment of resectable locally advanced esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | 4 | 400 | | Camrelizumab + Albumin Paclitaxel + Cisplatin ;Albumin Paclitaxel + Cisplatin | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Research projects of natural science universities in Anhui Province | Esophageal Squamous Cell Carcinoma | | | | |
ChiCTR2100053476: A single-arm clinical study of nitrozumab in combination with concurrent radiotherapy for unresectable locally advanced squamous oesophageal cancer |
|
|
| Not yet recruiting | 4 | 30 | | Nimotuzumab, Albumin paclitaxel, Cisplatin, radiotherapy | Cangzhou Central Hospital; Cangzhou Central Hospital, No | Esophageal neoplams | | | | |
ChiCTR2000040042: A prospective clinical study of albumin paclitaxel combined with platinum for first-line chemotherapy for advanced or recurrent or metastatic cervical cancer |
|
|
| Not yet recruiting | 4 | 30 | | Albumin Paclitaxel | Beijing Cancer Hospital; Beijing Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd. | cervical cancer | | | | |
RNPLS-01, NCT06169410: Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer |
|
|
| Recruiting | 4 | 140 | RoW | nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab, nab-paclitaxel, lobaplatin, and S-1 | Yang Jianjun, PhD | Advanced Gastric Cancer | 12/25 | 12/25 | | |
ChiCTR2000036223: A clinical study of intraperitoneal and intravenous Nab-Paclitaxel plus S-1 for gastric cancer with peritoneal metastasis complicated with malignant ascites |
|
|
| Recruiting | 4 | 20 | | intraperitoneal and intravenous Nab-Paclitaxel plus S-1 | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Ouyi Pharmaceutical Co., Ltd | Gastric Cancer | | | | |
ChiCTR2100042599: Surgical application of neoadjuvant therapy modality in pancreatic cancer |
|
|
| Recruiting | 4 | 120 | | nab-paclitaxel, and gemcitabine ; nab-paclitaxel, and gemcitabine ;nab-paclitaxel, and gemcitabine | West China Hospital of Sichuan University; West China Hospital of Sichuan University, not known | pancreatic cancer | | | | |
ChiCTR2100045844: A single-arm, prospective, exploratory clinical study of camrelizumab combined with albumin-bound paclitaxel and apatinib mesylate for first-line treatment of unresectable pancreatic cancer |
|
|
| Recruiting | 4 | 60 | | Camrelizumab, albumin-bound paclitaxel and apatinib mesylate | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co. LTD | pancreatic cancer | | | | |
ChiCTR2100051154: A prospective, multicenter, randomized controlled clinical study of camrelizumab combined with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous cell carcinoma |
|
|
| Recruiting | 4 | 120 | | Camrelizumab(200mg,d1) combined with albumin bound paclitaxel(175mg/m2,d1) and carboplatin(AUC=5,d1), Q3W,for 2 cycle ;Camrelizumab(200mg,d1) combined with albumin bound paclitaxel(175mg/m2,d1) and carboplatin(AUC=5,d1), Q3W,for 4 cycle | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Jiangsu Hengrui Medicine Co., Ltd. | esophageal squamous cell carcinoma | | | | |
NCT06230055: Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis |
|
|
| Recruiting | 4 | 48 | RoW | Ommaya reservoir, Systematic chemotherapy | Fudan University | HER2-negative Breast Cancer, Leptomeningeal Metastasis | 01/26 | 01/27 | | |
PILOT, NCT06357598: Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer |
|
|
| Recruiting | 4 | 30 | RoW | Tislelizumab, PD-1 antibody, Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC), chemotherapeutic drug, Carboplatin or Cisplatin, Surgery | The Affiliated Hospital of Qingdao University | Non-small-cell Lung Cancer (NSCLC) | 12/24 | 12/25 | | |
MA-NSCLC-II-039, NCT06276933: A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Not yet recruiting | 4 | 104 | NA | Camrelizumab + chemotherapy+Thalidomide, Camrelizumab + chemotherapy+placebo | Tongji University, Shanghai Pulmonary Hospital, Shanghai, China | Lung Cancer, Camrelizumab | 11/25 | 11/26 | | |
ChiCTR2000034101: Efficacy and safty of Nab-paclitaxel combined with tissue brachytherapy for recurrent cervical cancer after radiotherapy and chemotherapy: a multicenter, open clinical study |
|
|
| Not yet recruiting | 4 | 80 | | nab-paclitaxel | Affiliated Hospital of Inner Mongolia Medical University; Affiliated Hospital of Inner Mongolia Medical University, Ouyi Pharmaceutical Co., Ltd | cervical cancer | | | | |
NCT06388135: Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 4 | 80 | NA | Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin | Yang Jianjun, PhD | Esophageal Squamous Cell Carcinoma | 05/26 | 05/27 | | |
NCT04554524: Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma |
|
|
| Recruiting | 4 | 40 | RoW | Chemotherapy+Pembrolizumab., Carbo-paclitaxel/ nab-paclitaxel | Tang-Du Hospital | Thymoma and Thymic Carcinoma | 07/24 | 07/24 | | |
NCT06578299: Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer |
|
|
| Not yet recruiting | 4 | 100 | NA | Inetetamab and Paclitaxel ± Pertuzumab | Fudan University | Breast Cancer Stage IV | 03/26 | 08/27 | | |
ChiCTR2300068184: Camrelizumab combined with chemotherapy in neoadjuvant treatment of gastroesophageal junction cancer: A single-arm, single-center, exploratory clinical study |
|
|
| Recruiting | 4 | 87 | | Camrelizumab 200mg, d1; Albumin paclitaxel 100mg/m^2, d1; S-1 60mg/m^2, bid, d1-14; Oxaliplatin 130mg/m^2, d1, q3w, 2-4 cycles in total. | Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, Self-funded | Gastroesophageal junction carcinoma | | | | |
ChiCTR2300068185: Camrelizumab combined with chemotherapy in neoadjuvant treatment of esophageal cancer: A single-arm, single-center, exploratory clinical study |
|
|
| Recruiting | 4 | 67 | | Camrelizumab 200mg, d1; Albumin paclitaxel 100mg/m^2, d1; Tegio 60mg/m^2/d, d1-14; Nedaplatin 85 mg/m^2, d1, d2, d3; Q3w, 2-4 cycles in total. | Affiliated Cancer Hospital of Shandong First Medical University; Affiliated Cancer Hospital of Shandong First Medical University, Self-funded | esophageal cancer | | | | |
ChiCTR2300071546: Neoadjuvant camrelizumab combined with chemotherapy in esophageal squamous cell carcinoma |
|
|
| Completed | 4 | 35 | | Patients were treated with 4 cycles of the following drugs intravenously: camrelizumab (200 mg on day 1, every 3 weeks), nab-paclitaxel (260 mg/m2 on day 1, every 3 weeks), and carboplatin (area under the curve of 5 mg/mL/min on day 1, every 3 weeks). | People’s Hospital of Yangzhong; People’s Hospital of Yangzhong, None | Esophageal squamous cell carcinoma | | | | |
ChiCTR2400085451: An exploratory study of camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma |
|
|
| Completed | 4 | 40 | | Camrelizumab (200mg, d1) and albumin-bound paclitaxel (125mg/m2, d1, d8) were administered every 3 weeks until disease progression, toxicity intolerance, initiation of new antineoplastic therapy, withdrawal of knowledge, or withdrawal from study treatment as judged by the investigator.; Camrelizumab (200mg, d1) and albumin-bound paclitaxel (125mg/m2, d1, d8) were administered every 3 weeks until disease progression, toxicity intolerance, initiation of new antineoplastic therapy, withdrawal of knowledge, or withdrawal from study treatment as judged by the investigator. | Cancer Hospital Affiliated to Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University, Jiangsu Hengrui Pharmaceutical Co. LTD | esophageal squamous carcinoma ，； | | | | |
NCT05291910: Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer |
|
|
| Not yet recruiting | 4 | 70 | RoW | Inetetamab, Toripalimab, Albumin-Bound Paclitaxel | Chinese Academy of Medical Sciences | Breast Cancer | 12/24 | 12/25 | | |
ChiCTR2200062653: Clinical study of transformation treatment of tislelizumab combined with albumin paclitaxel and S-1 in patients with unresectable locally advanced and metastatic gastric cancer |
|
|
| Not yet recruiting | 4 | 121 | China | Tislelizumab combined with albumin paclitaxel and S-1 ;Tislelizumab combined with albumin paclitaxel and S-1 | The First Affiliated Hospital of Zhejiang University ; The First Affiliated Hospital of Zhejiang University, Fujian Province Medical Volunteer Association | Gastric cancer | | | | |
ChiCTR2300067853: Genetic population-based pharmacokietics of individualized dosing of albumin-bounded paclitaxel in the treatment of solid tumors |
|
|
| Not yet recruiting | 4 | 68 | | 1) Weekly therapy: every 4 weeks is a cycle, and albumin paclitaxel is about 125 mg/m2; Or 2) Three weeks of treatment, albumin paclitaxel is about 260 mg/m2, d1, q3w. | Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou Municipal Science and Technology Bureau Foundation | Solid tumors | | | | |
NeoSTEP, NCT05843292: Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 4 | 48 | NA | Taxane and Carboplatin, Short-term Sintilimab, Surgery | Shanghai Jiao Tong University School of Medicine, Innovent Biologics, Inc., CSPC Ouyi Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 12/24 | 12/34 | | |
| Not yet recruiting | 4 | 30 | | Adbelimab + Apatinib mesylate + albumin bound paclitaxel | He'nan Cancer Hospital; He'nan Cancer Hospital, Self-funded | SLC | | | | |
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma |
|
|
| Recruiting | 4 | 136 | Europe | Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed | Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Non-Small Cell Lung Cancer Metastatic | 10/25 | 10/26 | | |
ChiCTR2000039578: A prospective, open, multicenter, randomized controlled trial for the effect of albumin-bound paclitaxel combined with cisplatin versus epirubicin combined with cyclophosphamide sequential docetaxel neoadjuvant therapy for triple negative breast cancer |
|
|
| Recruiting | 4 | 240 | | Paclitaxel (Albumin Bound）combined with cisplatin ;Epirubicin combined with cyclophosphamide sequential docetaxel | Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd | Breast cancer | | | | |
NCT04136782: Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 110 | RoW | Albumin-bound paclitaxel combined with carboplatin, Albumin-bound paclitaxel+carboplatin group, Epirubicin combined with docetaxel, Epirubicin+docetaxel group | Shengjing Hospital | Breast Cancer | 11/25 | 11/26 | | |
ChiCTR2300078954: A Study on the Combination of Separizumab and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous Cell carcinoma |
|
|
| Not yet recruiting | 4 | 32 | | Received 3 cycles of treatment with combination of cyparizumab, albumin bound paclitaxel, and cisplatin | Changzhou First People's Hospital; Changzhou First People's Hospital, self-funding | Localized advanced head and neck squamous cell carcinoma | | | | |
NCT05035147: Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer |
|
|
| Recruiting | 4 | 934 | RoW | albumin-bound paclitaxel, gemcitabine | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 04/26 | 12/26 | | |
ChiCTR2300075011: Consolidation therapy of Adebrelimab for stage III unresectable NSCLC after concurrent radiotherapy and chemotherapy (cCRT combined with or without Adebrelimab) |
|
|
| Recruiting | 4 | 120 | | Adebrelimab+pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin，The dose of chest radiation therapy is 60-66Gy/30-33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity. ;pemetrexed/Albumin paclitaxel+ carboplatin/cisplatin，The dose of chest radiation therapy is 60-66Gy/30-33f. Consolidation therapy After four cycles of combined treatment, the patients received a dosing cycle of 1200 mg Q3W of Adebrelimab. Until PD or intolerable toxicity. | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Self-financing | non-small cell lung cancer | | | | |
ChiCTR1900026499: Albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer: a multicenter randomized controlled phase IV clinical trial |
|
|
| Not yet recruiting | 4 | 110 | | albumin-bound paclitaxel combined with carboplatin ;epirubicin combined with docetaxel | Shengjing Hospital of China Medical University; 中国医科大学附属盛京医院, Self-financing | Breast Cancer | | | | |
ChiCTR2300076150: Efficacy and safety of sintilimab in combination with fruquintinib and albumin-bound paclitaxel in advanced HER-2 negative gastric cancer after first-line checkpoint inhibitor combined with chemotherapy failure: a single-arm, prospective, exploratory clinical study |
|
|
| Not yet recruiting | 4 | 46 | | sintilimab+fruquintinib+albumin-bound paclitaxel | Jiangsu Province Hospital; Jiangsu Province Hospital, Self-financed | gastric cancer | | | | |
ChiCTR2300078968: Prospective, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Nabpaclitaxel in Extensive Stage Small Cell Lung Cancer Who Failed Prior Immunotherapy |
|
|
| Recruiting | 4 | 120 | | Adebrelimab 1200 mg IV, Q3W, D1; apatinib, PO, 250 mg, QD; nabpaclitaxel, IV, 200 mg/m2, q3w; after four cycles, adebrelimab and apatinib were maintained until disease progression or intolerance.; Adebrelimab 1200 mg IV, Q3W, D1; apatinib, PO, 250 mg, QD; until disease progression or intolerance.; Apatinib, PO, 250 mg, QD; nabpaclitaxel, IV, 200 mg/m2, q3w; after four cycles, apatinib was maintained until disease progression or intolerance. | Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jiangsu Hengrui Pharmaceutical Co. LTD | Small cell lung cancer | | | | |
ChiCTR2300079055: Adebrelimab combined with radiotherapy and chemotherapy in the treatment of recurrent esophageal squamous cell carcinoma-A single arm, phase II clinical study |
|
|
| Recruiting | 4 | 49 | | Chemotherapy: The preferred option is to combine albumin paclitaxel with platinum, Or combined with cisplatin or carboplatin; Immunization: Before chemotherapy on the first day of each cycle, intravenous infusion of 1200mg of Adelbolizumab, Q3W; Radiation therapy: using radiation therapy for the affected field of the recurrent site; Three dimensional conformal or intensity modulated radiotherapy technology, 1.8Gy/QD/45Gy, must be accompanied by chemotherapy and radiation therapy; During the maintenance treatment phase, subjects received maintenance treatment with adelbizumab every 3 weeks. Until disease progression, intolerable toxicity, or patient death occurs. | Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital, Self-financing | esophageal cancer | | | | |
NCT05420454: A Study for the Neoadjuvant Treatment of Breast Cancer |
|
|
| Recruiting | 4 | 1576 | RoW | Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 06/27 | 12/27 | | |
NCT05420467: A Study for the Adjuvant Treatment of Breast Cancer |
|
|
| Recruiting | 4 | 2413 | RoW | Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Nab paclitaxel, Epirubicin, Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | Breast Cancer | 07/27 | 12/27 | | |
ChiCTR2400082388: Clinical study of pyrrolitinib maleate tablets combined with albumin paclitaxel in adjuvant treatment of HER2 positive early breast cancer |
|
|
| Not yet recruiting | 4 | 150 | | Pyrrolitinib (D1-365, 400mg, qd, for a total of 52 weeks)Albumin paclitaxel (125mg/m2, D1, 8, q3w, 6 cycles in total)Loperamide (D1-7, 4mg, tid, D8-21 days 4mg, bid, subsequent use as needed); Pyrrolitinib (D1-21, 320mg, qd; D22-365, 400mg, qd, 52 weeks)Albumin paclitaxel (125mg/m2, D1, 8, q3w, 6 cycles in total)Loperamide (D1-7, 4mg, tid, D8-21, 4mg, bid, to be used as needed) | Weihai Municipal Hospital; Weihai Municipal Hospital, Weihai Municipal Hospital | Breast cancer | | | | |
NIPPON, jRCTs031210013: A Multicenter Randomized Phase III Study comparing Pembrolizumab + Platinum Combination Chemotherapy with Nivolumab + Ipilimumab + Platinum Combination Chemotherapy for Treatment-naive Advanced Non-Small Cell Lung Cancer without Driver Gene alteration |
|
|
| Active, not recruiting | 3 | 422 | Japan | pemetrexed - Generic mfg., Keytruda (pembrolizumab) - Merck (MSD), paclitaxel - Generic mfg., Opdivo (nivolumab) - BMS, Yervoy (ipilimumab) - BMS | Kyushu University Hospital, National Cancer Center Japan | Treatment-naive advanced non-small cell lung cancer;Non-squamous NSCLC | | | | |
ACTRN12613000119796: Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer |
|
|
| Active, not recruiting | 3 | 632 | | | Fondazione Michelangelo, Investigator Initiated Research Grant from Celgene | Breast Cancer | | | | |
| Completed | 3 | 632 | Europe, RoW | Abraxane, Nab-paclitaxel, Paclitaxel, No specific brand name | Fondazione Michelangelo | Breast Cancer | 09/16 | 03/23 | | |
|
2016-001332-35: Investigating a new combination of chemotherapy (nab-paclitaxel and gemcitabine) for patients with unresectable pancreatic cancer without metastasis. Een onderzoek naar de combinatie van de chemotherapie nab-paclitaxel en gemcitabine bij lokaal doorgegroeide alvleesklierkanker. |
|
|
| Ongoing | 3 | 136 | Europe | Powder for suspension for injection, Abraxane | Academic Medical Center Amsterdam, Academic Medical Center Amsterdam, Celgene coorporatoin | Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition., Unresectable pancreatic cancer without metastases., Diseases [C] - Cancer [C04] | | | | |
KEYNOTE-407, NCT02775435 / 2016-000229-38: A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/) |
|
|
| Completed | 3 | 559 | NA | Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Nab-paclitaxel, ABRAXANE®, Carboplatin, PARAPLATIN®, Saline placebo for pembrolizumab | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer | 04/18 | 09/23 | | |
|
|
|
|
|
|
|
|
2019-002288-84: Testing the delivery of an anti-cancer drug, gemcitabine, directly into the pancreas in patients with pancreatic cancer |
|
|
| Not yet recruiting | 3 | 320 | Europe | Gemcitabine, Concentrate for solution for injection | RenovoRx, Inc., RenovoRx | Locally advanced pancreatic cancer, Pancreatic cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2019-003064-50: Phase III Study of HLX10 in Combination with Chemotherapy versus Chemotherapy alone as First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Not yet recruiting | 3 | 516 | Europe | HLX10, HLX10, Concentrate for solution for infusion | Shanghai Henlius Biotech, Inc., Shanghai Henlius Biotech, Inc. | First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC), First-Line Therapy for Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |
| Completed | 3 | 125 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Carboplatin, PARAPLATIN®, Saline placebo for pembrolizumab | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer | 09/20 | 09/23 | | |
|
| Completed | 3 | 360 | RoW | Tislelizumab, BGB-A317, Tevimbra, Paclitaxel, Nab-paclitaxel, Carboplatin | BeiGene | Non-Small Cell Lung Cancer | 09/20 | 04/23 | | |
|
|
|
|
| Active, not recruiting | 3 | 1186 | Europe, Japan, US, RoW | Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin | AstraZeneca | Non Small Cell Lung Cancer NSCLC | 03/21 | 12/26 | | |
|
|
|
|
|
KEYNOTE-355, NCT02819518 / 2016-001432-35: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/) |
|
|
| Completed | 3 | 882 | NA | Pembrolizumab, MK-3475, KEYTRUDA®, Nab-paclitaxel, ABRAXANE®, Paclitaxel, TAXOL®, Gemcitabine, GEMZAR®, Carboplatin, PARAPLATIN®, Normale Saline Solution | Merck Sharp & Dohme LLC | Triple Negative Breast Cancer (TNBC) | 06/21 | 10/23 | | |
|
|
|
|
|
|
CANOPY-1, NCT03631199 / 2018-001547-32: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects |
|
|
| Active, not recruiting | 3 | 673 | Europe, Canada, Japan, US, RoW | canakinumab, ACZ885, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed | Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 08/21 | 06/27 | | |
|
|
|
2021-000591-10: Study of efficacy and safety of NIS793 in combination with standard of care (SOC) chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) |
|
|
| Ongoing | 3 | 490 | Europe | nab-paclitaxel, gemcitabine, NIS793, Concentrate for solution for infusion, Powder for solution for infusion | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Pancreatic ductal adenocarcinoma, Pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 557 | Europe, Canada, Japan, US, RoW | Trastuzumab deruxtecan (DS-8201a), DS-8201a, Capecitabine, Eribulin, Gemcitabine, Paclitaxel, Nab-paclitaxel | Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca | Breast Cancer | 01/22 | 10/25 | | |
|
|
|
|
CTONG2003, NCT04768075: Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC |
|
|
| Not yet recruiting | 3 | 200 | NA | Camrelizumab, SHR-1210, Placebo, Simulator of Camrelizumab, Cisplatin, cisplatinum, Carboplatin, Carboplat, Pemetrexed, Pemetrexed disodium, Paclitaxel, Paclitaxel injection, Albumin paclitaxel, Nab-paclitaxel | Guangdong Association of Clinical Trials | Non-Small-Cell Lung Cancer | 04/22 | 04/24 | | |
| Active, not recruiting | 3 | 270 | Europe | Irinotecan Liposomal Injection [Onivyde], Nal-IRI | AIO-Studien-gGmbH, Crolll Gmbh, Servier Deutschland GmbH | Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer | 05/22 | 05/23 | | |
NAPOLI-3, NCT04083235 / 2018-003585-14: A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment |
|
|
| Active, not recruiting | 3 | 770 | Europe, Canada, US, RoW | Irinotecan Liposomal Injection, Onivyde®, Nal-IRI, Oxaliplatin, Eloxatin®, 5Fluorouracil, Adrucil®, flurouracil, 5-FU, Leucovorin, Folinic Acid, Nab-paclitaxel, Abraxane®, Gemcitabine, Gemzar® | Ipsen | Metastatic Adenocarcinoma of the Pancreas | 07/22 | 12/24 | | |
TIGeR-PaC, NCT03257033: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC |
|
|
| Recruiting | 3 | 190 | Europe, US | Gemcitabine, Gemzar, nab-paclitaxel, Abraxane, RenovoCath | RenovoRx | Locally Advanced Pancreatic Cancer | 06/26 | 09/26 | | |
HLX10-013-TNBCneo, NCT04301739: to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 522 | NA | HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide, Placebo | Shanghai Henlius Biotech | Triple Negative Breast Cancer | 09/22 | 04/27 | | |
NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor |
|
|
| Recruiting | 3 | 354 | RoW | PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only | Fudan University | Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy | 09/25 | 09/27 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
2022-000662-18: A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Klinikai vizsgálat a nab-paklitaxellel kombinált relacorilanttal (vizsgálati készítmény) petefészek, petevezeték vagy peritoneális rákban szenvedő betegeknél |
|
|
| Ongoing | 3 | 360 | Europe | Relacorilant, Abraxane, CORT125134, Nab-paclitaxel, Capsule, soft, Powder for dispersion for infusion, Abraxane | Corcept Therapeutics Incorporated, Corcept Therapeutics Incorporated | Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer, Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer, Diseases [C] - Cancer [C04] | | | | |
2022-003157-55: Clinical study on the efficacy and safety of Tumor Treating Fields, atezolizumab, gemcitabine and nab-paclitaxel as first line treatment for metastatic pancreatic carcinoma. |
|
|
| Ongoing | 3 | 76 | Europe | Concentrate for solution for injection/infusion, Tecentriq 840 mg concentrate for solution for infusion | Novocure GmbH, Novocure GmbH | Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Metasztatikus duktális hasnyálmirigy-adenokarcinóma (mPDAC), Pancreatic Cancer Hasnyálmirigyrák, Diseases [C] - Cancer [C04] | | | | |
KEYNOTE-A86, NCT04956692 / 2020-002729-27: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) |
|
|
| Active, not recruiting | 3 | 531 | Europe, Japan, US, RoW | Pembrolizumab SC, Pembrolizumab IV, MK-3475, KEYTRUDA®, SCH 900475, Paclitaxel, Nov-Onxol, Onxol, Paclitaxel Novaplus, Taxol, Nab-Paclitaxel, Abraxane, Nanoparticle albumin-bound paclitaxel, Carboplatin, Paraplatin, Paraplatin NovaPlus, Cisplatin, Platinol-AQ, Pemetrexed, LY231514, Alimta, Pemetrexed Disodium | Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | Non-Small Cell Lung Cancer | 04/23 | 10/26 | | |
NCT04335006: A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. |
|
|
| Terminated | 3 | 80 | RoW | Carelizumab, SHR-1210, Nab-paclitaxel, Apatinib | Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer, Triple Negative Breast Cancer | 04/23 | 04/23 | | |
| Completed | 3 | 278 | Europe, RoW | Carboplatin, Carboplatin Teva, Abraxane, nab-paclitaxel, MPDL3280A, Atezolizumab, Surgery, Anthra | Fondazione Michelangelo | Invasive Ductal Breast Carcinoma | 01/24 | 01/24 | | |
EPIK-B3, NCT04251533 / 2019-002637-11: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss |
|
|
| Active, not recruiting | 3 | 137 | Europe, US, RoW | alpelisib, BYL719, placebo, alpelisib-matching placebo, nab-paclitaxel, abraxane | Novartis Pharmaceuticals | Triple Negative Breast Neoplasms | 05/23 | 01/25 | | |
|
NCT03398291: Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy |
|
|
| Recruiting | 3 | 300 | RoW | Synchronous resection of primary pancreatic cancer and liver oligometastasis, Standard chemotherapy | Fudan University | Pancreatic Cancer, Liver Metastases, Surgery | 06/23 | 06/25 | | |
